又一款“全程一次用药”的国产流感口服药上市，张文宏团队牵头研发

Group 1 - The National Medical Products Administration (NMPA) has approved the oral antiviral drug Maraslavir (brand name: Jike Shou) for the treatment of uncomplicated influenza in previously healthy adults, specifically targeting both influenza A and B viruses [1] - Maraslavir is a new generation PA endonuclease inhibitor with broad-spectrum antiviral properties, effective against various strains including highly pathogenic avian influenza [1] - The drug was developed by a team led by Zhang Wenhong from the National Center for Infectious Disease Medicine and Huashan Hospital, with efficacy and safety data published in the journal Clinical Microbiology and Infection [1] Group 2 - Maraslavir is positioned as a domestic alternative to the well-known influenza drug Baloxavir (brand name: Sufuda), which has faced supply risks [2] - The recently approved domestic antiviral drug Masuravir (brand name: Yisuda) is also aimed at treating uncomplicated influenza in healthy adolescents and adults aged 12 and above [2] - Despite the introduction of more domestic antiviral drugs, the pricing of these new products may be higher than imported counterparts, with Masuravir priced around 320 yuan for 20mg*2 tablets, compared to Baloxavir's price of less than 200 yuan [2] Group 3 - Clinical studies indicate that the resistance mutation rates for Masuravir against influenza A H1N1 and H3N2 are low, at 0.7% and 0.9% respectively, with only one mutation site detected for H1N1 [2] - No resistance mutations were detected in patients with influenza B, suggesting a low risk of resistance and suitability for long-term clinical use [2]